ARA-290
aka Cibinetide
Mechanism
ARA-290 (Cibinetide) is a synthetic 11-amino-acid peptide derived from the helix-B surface of erythropoietin (EPO), developed by Araim Pharmaceuticals. It selectively activates the innate repair receptor (IRR) for anti-inflammatory, tissue-protective, and neuroprotective signaling without stimulating erythropoiesis. ARA-290 is not FDA-approved; it has received FDA Fast Track and Orphan Drug designations for sarcoidosis-associated small fiber neuropathy and remains in clinical development as of April 2026.
Identification
| CAS number | 1208243-50-8 |
|---|---|
| Molecular formula | C51H84N16O21 |
| Sequence | UEQLERALNSS |
| Typical dose | 4 mg/day subcutaneous (clinical trial dosing for diabetic neuropathy and sarcoidosis-associated small fiber neuropathy) |
| Half-life | ~20 minutes terminal half-life (after 4 mg SC injection; biological effect may persist 24–72 hours) |
Vendors selling ARA-290
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Glacier Aminos | 10 mg | $54.99 | — | 99 |
| BioLongevity Labs | 15 mg | $95.00 | — | 96 |
| Orbitrex Peptides | — | $49.99 | — | 95 |
| Ion Peptide | — | $59.00 | — | 95 |
| Peptide Tech | 12 mg | $59.99 | — | 94 |
| Mile High Compounds | — | $49.99 | — | 94 |
| Riptide Wellness | — | $80.99 | — | 92 |
| Skye Peptides | 16 mg | $84.00 | — | 90 |
| Peptidology | 10 mg | $54.99 | — | 89 |
| Peptidology | 11 mg | $54.99 | — | 89 |
| Peptide Plugs | 10 mg | $50.00 | — | 89 |
| Verified Peptides | 12 mg | $65.00 | — | 86 |
| EZ Peptides | 10 mg | $48.00 | — | 85 |
| Simple Peptide | 10 mg | $76.00 | — | 85 |
| Peptidegurus | 10 mg | — | — | 84 |
| Peptidegurus | 16 mg | — | — | 84 |
| Ascension Peptides | 10 mg | $79.99 | — | 84 |
| OROS Research | 30 mg | — | — | 79 |
| OROS Research | 32 mg | — | — | 79 |
| Qing Li Peptide | — | — | — | 63 |
| Certified Peptides | 16 mg | $92.00 | — | 62 |
| Peptiatlas | — | — | — | 51 |
| Mandy | 10 mg | $58.00 | — | 43 |
| Strate Labs | 10 mg | $24.95 | — | — |
| AMC Essentials | 30 mg | $99.99 | — | — |
| Alpha Omega | 10 mg | $76.00 | — | — |
| Atomik Labz | 16 mg | $79.00 | — | — |
| Biotech Peptides | 16 mg | $88.00 | — | — |
| Bulk Peptides | 10 mg | $180.00 | — | — |
| Core Peptides | 16 mg | $92.00 | — | — |
| Flawless Compounds | — | — | — | — |
| Genetic Peptide | 5 mg | $50.00 | — | — |
| Genetic Peptide | 16 mg | $50.00 | — | — |
| Kimera Chems | — | $51.99 | — | — |
| Modern Research Peptides | 10 mg | $37.99 | — | — |
| Paramount Peptides | 14 mg | $77.00 | — | — |
| Peptide Crafters | 16 mg | $50.00 | — | — |
| Peptira | — | $49.00 | — | — |
| Platinum Lion | — | $69.99 | — | — |
| Solution Peptides | 16 mg | $79.00 | — | — |
| Soma Peptides | 16 mg | $76.00 | — | — |
| Southern Aminos | 10 mg | $44.25 | — | — |
Research
Type 2 diabetes (T2D) is associated with cognitive impairment, with executive functions such as cognitive flexibility being particularly vulnerable.
source →A wound has been defined as a disruption of tissue integrity. Pain, bleeding, and the risk of infection are inherent features of wounds, while chronic wounds are often accompanied by serous exudate.
source →Cardiology is continually evolving towards increased personalization with targeted diagnostics and therapeutics.
source →Alzheimer's disease (AD) pathology is characterized by amyloid-β (Aβ) deposition and tau hyper-phosphorylation, accompanied by a progressive cognitive decline. Monocytes have been recently shown to play a major role in modulating Aβ pathology, and thereby have been pointed as potential therapeutic targets.
source →Objectives Myocardial infarction caused by ischemia of heart tissue is the main reason for death worldwide; therefore, early detection can reduce mortality and treatment costs.
source →Background Erythropoietin exerts anti-inflammatory, antiapoptotic, and cytoprotective effects in addition to its hematopoietic action. A nonhematopoietic erythropoietin analogue, ARA 290, has similar properties.
source →ARA 290 is an erythropoietin-derived polypeptide that possesses analgesic and tissue protective effect in many diseases such as diabetes and cancer.
source →ARA 290-DMO is a prospective, open label, interventional, single centre, investigator led, phase II trial to examine the effect of ARA 290 on diabetic macular oedema in patients with type 1 or 2 diabetes.
source →Although erythropoietin ameliorates experimental type 2 diabetes with neuropathy, serious side effects limit its potential clinical use. ARA 290, a nonhematopoietic peptide designed from the structure of erythropoietin, interacts selectively with the innate repair receptor that mediates tissue protection.
source →Introduction Painful peripheral neuropathy is a common, difficult-to-treat complication associated with a variety of diseases, including diabetes mellitus and sarcoidosis.
source →Background Neuropathic pain is a difficult to treat disorder arising from central or peripheral nervous system lesions. The etiology of neuropathic pain consists of several overlapping pathways converging into an exaggerated pain state with symptoms such as allodynia and hyperalgesia.
source →The purpose of this study is to determine whether ARA 290, a new class of compound, is effective in the treatment of the neuropathic symptoms of sarcoidosis.
source →Small nerve fiber loss and damage (SNFLD) is a frequent complication of sarcoidosis that is associated with autonomic dysfunction and sensory abnormalities, including pain syndromes that severely degrade the quality of life.
source →The purpose of this study is to determine whether a non-hematopoietic erythropoietin analogue, ARA 290, exerts beneficial effects on blood glucose levels and insulin secretion in persons with prediabetes (impaired glucose tolerance, IGT, or impaired fasting glucose, IFG), or drug-naive type 2 diabetes.
source →ARA 290 (a peptide designed to activate the innate repair receptor that arrests injury and initiates cytoprotection, antiinflammation and healing) reduces allodynia in preclinical neuropathy models.
source →Studies on the hormone Erythropoietin (EPO) have indicated that EPO may have antidepressant properties. However, EPO may cause serious side-effects with repeated administration (thrombosis), which limits its usefulness as an antidepressant.
source →